

Dr Christophe Ferrand is a research director at the French Blood center in the INSERM UMR1098 RIGHT, Besançon, France. He is interested and involved in the field of cell and gene therapy since more 25 years, especially in T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect. He is the co-founder and currently Director of R&D of CanCell Therapeutics Company.

With competences in immunology, molecular biology, vectorology (lenti or retrovirus), cell culture, gene therapy, suicide gene therapy, deep experience in translational research, he provide an strong background in the field of Immunotherapies, as CART-cells, Transgenic TCR and others.